Type of non Hodgkin's lymphoma-Follicular lymphoma Posts on Medivizor
Navigation Menu

Type of non Hodgkin’s lymphoma-Follicular lymphoma Posts on Medivizor

Comparing two doses of radiotherapy for slow-growing non-Hodgkin lymphomas.

Comparing two doses of radiotherapy for slow-growing non-Hodgkin lymphomas.

Posted by on Feb 28, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors compared a high-dose radiation (24 Gy) in 12 parts with a low-dose radiation (4 Gy) in 2 parts in patients with slow-growing non-Hodgkin lymphomas (NHLs). The study found that the best radiotherapy dose for slow-growing NHLs is 24 Gy in 12 parts after a 5-year follow-up. Some background The current standard of care for...

Read More

Comparing rituximab to newer anti-CD20 monoclonal antibodies for induction therapy of CD20+ B-cell non-Hodgkin lymphomas

Comparing rituximab to newer anti-CD20 monoclonal antibodies for induction therapy of CD20+ B-cell non-Hodgkin lymphomas

Posted by on Feb 28, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to compare standard therapy Rituximab (Rituxan) to newer anti-CD20 monoclonal antibodies (mAbs) such as obinutuzumab (Gazyva), ofatumumab (Arzerra), 131I-tositumomab (Bexxar), and 90Y-ibritumomab tiuxetan (Zevalin) for the treatment of patients with B-cell non-Hodgkin lymphomas (B-NHL). The authors concluded...

Read More

How effective is rituximab, bendamustine, mitoxantrone (R-BM) and rituximab consolidation as a treatment regimen for elderly patients with advanced follicular lymphoma?

How effective is rituximab, bendamustine, mitoxantrone (R-BM) and rituximab consolidation as a treatment regimen for elderly patients with advanced follicular lymphoma?

Posted by on Feb 14, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate if rituximab (Rituxan), bendamustine (Treanda), and mitoxantrone (Novantrone) or R-BM followed by rituximab consolidation was a safe and effective treatment in older patients with follicular lymphoma (FL). The authors concluded that this treatment provided durable responses and was well tolerated in...

Read More

Is rituximab maintenance effective long-term for follicular lymphoma after an autologous stem cell transplant?

Is rituximab maintenance effective long-term for follicular lymphoma after an autologous stem cell transplant?

Posted by on Feb 14, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors reviewed rituximab (Rituxan) maintenance (RM) therapy in patients with relapsed follicular lymphoma (FL) treated with an autologous stem cell transplant (ASCT). The study found that RM after ASCT delayed FL relapse after a 12-year follow up. Some background Rituximab and chemotherapy have improved the outcomes of...

Read More

Long-term outcomes of idelalisib treatment for patients with relapsed painless lymphoma

Long-term outcomes of idelalisib treatment for patients with relapsed painless lymphoma

Posted by on Jan 31, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study reported the long-term effectiveness and safety outcomes of treatment with idelalisib (Zydelig) after a longer follow-up of patients with indolent (painless) non-Hodgkin lymphoma. The data showed that idelalisib treatment improved the overall survival of these patients in the long-term. Some background Non-Hodgkin...

Read More

Effects of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin lymphoma in a resource-limited country

Effects of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin lymphoma in a resource-limited country

Posted by on Dec 6, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study analyzed outcomes of high-dose therapy (HDT) with autologous hematopoietic stem cell transplantation (AHSCT) for patients with non-Hodgkin lymphoma (NHL) in a resource-limited country and evaluated whether upfront AHSCT could be an effective treatment. The authors found promising outcomes of this treatment in a resource-limited...

Read More

Evaluating zanubrutinib combined with obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma

Evaluating zanubrutinib combined with obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma

Posted by on Nov 2, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the combination of zanubrutinib (Brukinsa) and obinutuzumab (Gazyva) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and follicular lymphoma (FL). This study concluded that this combination was well tolerated and had promising responses in these patients.  Some...

Read More

Seeking patients with relapsed B-cell NHL or CLL for trial of kinase-blocking treatment

Seeking patients with relapsed B-cell NHL or CLL for trial of kinase-blocking treatment

Posted by on Oct 11, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study will evaluate a three-drug regimen for the treatment of relapsed B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL). The primary outcomes are how many patients respond to treatment or have a complete response (cancer no longer detectable). The study will take place in the United States. The details B-cell...

Read More

Looking for participants to test an experimental immunotherapy for relapsed non-Hodgkin lymphoma

Looking for participants to test an experimental immunotherapy for relapsed non-Hodgkin lymphoma

Posted by on Oct 11, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study will evaluate the antibody therapy odronextamab for patients with relapsed B-cell non-Hodgkin lymphoma (NHL). The primary outcomes will be how many patients respond to treatment, and how many have a complete response (cancer no longer detectable).  The details For B-cell NHL which has relapsed (returned) after...

Read More

Evaluating 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma

Evaluating 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma

Posted by on Oct 4, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study evaluated the safety and effectiveness of 177Lu-lilotomab satetraxetan (177LLS; Betalutin) in patients with relapsed/refractory (r/r) indolent non-Hodgkin lymphoma (iNHL). The main finding was that 177LLS was proven to be a valuable alternative treatment in such patients. Some background NHL is a type of lymphoma that spreads...

Read More